4-week trial finds Deep Intracranial Frequency Stimulation (DIFS) with escitalopram improves major depressive disorder symptoms in two-thirds of patients compared to one-third on medication alone.
Nexalin Technology announced positive results from a clinical study showing its non-invasive Deep Intracranial Frequency Stimulation (DIFS) technology, combined with escitalopram, significantly improved major depressive disorder symptoms in two-thirds of patients compared to one-third who received medication alone. The 4-week, double-blind, randomized, sham-controlled trial involved 66 participants.
June 26, 2024
4 Articles